Literature DB >> 31538675

Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition.

Robert B Conley1, Gemma Adib2, Robert A Adler3, Kristina E Åkesson4, Ivy M Alexander5, Kelly C Amenta6, Robert D Blank7,8, William Timothy Brox9, Emily E Carmody10, Karen Chapman-Novakofski11, Bart L Clarke12, Kathleen M Cody13, Cyrus Cooper14, Carolyn J Crandall15, Douglas R Dirschl16, Thomas J Eagen17, Ann L Elderkin18, Masaki Fujita19, Susan L Greenspan20, Philippe Halbout21, Marc C Hochberg22, Muhammad Javaid23, Kyle J Jeray24, Ann E Kearns12, Toby King25, Thomas F Koinis26, Jennifer Scott Koontz27,28, Martin Kužma29, Carleen Lindsey30, Mattias Lorentzon31,32,33, George P Lyritis34, Laura Boehnke Michaud35, Armando Miciano36, Suzanne N Morin37, Nadia Mujahid38, Nicola Napoli39,40, Thomas P Olenginski41, J Edward Puzas10, Stavroula Rizou34, Clifford J Rosen42,43, Kenneth Saag44, Elizabeth Thompson45, Laura L Tosi46, Howard Tracer47, Sundeep Khosla12, Douglas P Kiel48.   

Abstract

Osteoporosis-related fractures are undertreated, due in part to misinformation about recommended approaches to patient care and discrepancies among treatment guidelines. To help bridge this gap and improve patient outcomes, the American Society for Bone and Mineral Research assembled a multistakeholder coalition to develop clinical recommendations for the optimal prevention of secondary fracture among people aged 65 years and older with a hip or vertebral fracture. The coalition developed 13 recommendations (7 primary and 6 secondary) strongly supported by the empirical literature. The coalition recommends increased communication with patients regarding fracture risk, mortality and morbidity outcomes, and fracture risk reduction. Risk assessment (including fall history) should occur at regular intervals with referral to physical and/or occupational therapy as appropriate. Oral, intravenous, and subcutaneous pharmacotherapies are efficacious and can reduce risk of future fracture. Patients need education, however, about the benefits and risks of both treatment and not receiving treatment. Oral bisphosphonates alendronate and risedronate are first-line options and are generally well tolerated; otherwise, intravenous zoledronic acid and subcutaneous denosumab can be considered. Anabolic agents are expensive but may be beneficial for selected patients at high risk. Optimal duration of pharmacotherapy is unknown but because the risk for second fractures is highest in the early post-fracture period, prompt treatment is recommended. Adequate dietary or supplemental vitamin D and calcium intake should be assured. Individuals being treated for osteoporosis should be reevaluated for fracture risk routinely, including via patient education about osteoporosis and fractures and monitoring for adverse treatment effects. Patients should be strongly encouraged to avoid tobacco, consume alcohol in moderation at most, and engage in regular exercise and fall prevention strategies. Finally, referral to endocrinologists or other osteoporosis specialists may be warranted for individuals who experience repeated fracture or bone loss and those with complicating comorbidities (eg, hyperparathyroidism, chronic kidney disease).
© 2019 American Society for Bone and Mineral Research. © 2019 American Society for Bone and Mineral Research.

Entities:  

Keywords:  AGING; ANABOLICS; ANTIRESORPTIVES; OSTEOPOROSIS; SECONDARY FRACTURE PREVENTION

Mesh:

Substances:

Year:  2019        PMID: 31538675     DOI: 10.1002/jbmr.3877

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  36 in total

Review 1.  Orthogeriatric co-management for the care of older subjects with hip fracture: recommendations from an Italian intersociety consensus.

Authors:  Antonio De Vincentis; Astrid Ursula Behr; Giuseppe Bellelli; Marco Bravi; Anna Castaldo; Lucia Galluzzo; Giovanni Iolascon; Stefania Maggi; Emilio Martini; Alberto Momoli; Graziano Onder; Marco Paoletta; Luca Pietrogrande; Mauro Roselli; Mauro Ruggeri; Carmelinda Ruggiero; Fabio Santacaterina; Luigi Tritapepe; Amedeo Zurlo; Raffaele Antonelli Incalzi
Journal:  Aging Clin Exp Res       Date:  2021-07-21       Impact factor: 3.636

2.  FRAX and ethnicity.

Authors:  J A Kanis; C Cooper; B Dawson-Hughes; N C Harvey; H Johansson; M Lorentzon; E V McCloskey; J-Y Reginster; R Rizzoli
Journal:  Osteoporos Int       Date:  2020-09-04       Impact factor: 4.507

3.  Editorial: Secondary Fracture Prevention-What's Your System?

Authors:  Seth S Leopold
Journal:  Clin Orthop Relat Res       Date:  2020-04-23       Impact factor: 4.176

Review 4.  Osteoporotic hip and vertebral fractures in the Arab region: a systematic review.

Authors:  M Barake; R El Eid; S Ajjour; M Chakhtoura; L Meho; T Mahmoud; J Atieh; A M Sibai; G El-Hajj Fuleihan
Journal:  Osteoporos Int       Date:  2021-04-07       Impact factor: 4.507

5.  Bone metabolism subgroups identified as hip fracture patients via clustering.

Authors:  Evangelia Papakitsou; Ioanna Paspati; Stavroula Rizou; George P Lyritis
Journal:  Hormones (Athens)       Date:  2021-02-23       Impact factor: 2.885

Review 6.  How can the orthopedic surgeon ensure optimal vitamin D status in patients operated for an osteoporotic fracture?

Authors:  T Chevalley; M L Brandi; E Cavalier; N C Harvey; G Iolascon; C Cooper; D Hannouche; J-F Kaux; A Kurth; S Maggi; G Maier; K Papavasiliou; N Al-Daghri; M Sosa-Henríquez; N Suhm; U Tarantino; J-Y Reginster; R Rizzoli
Journal:  Osteoporos Int       Date:  2021-05-20       Impact factor: 4.507

7.  Improving osteoporotic vertebral deformity detection on chest frontal view radiograph by adjusted X-ray beam positioning.

Authors:  Er-Zhu Du; Wei-Hong Liu; Yì Xiáng J Wáng
Journal:  J Orthop Translat       Date:  2021-05-05       Impact factor: 5.191

Review 8.  Diagnosis and Management of Osteoporosis During COVID-19: Systematic Review and Practical Guidance.

Authors:  G Hampson; M Stone; J R Lindsay; R K Crowley; S H Ralston
Journal:  Calcif Tissue Int       Date:  2021-05-18       Impact factor: 4.333

Review 9.  The effect of intervention versus watchful waiting on disease progression and overall survival in smoldering multiple myeloma: a systematic review of randomized controlled trials.

Authors:  Ademola S Ojo; Somtochukwu G Ojukwu; Joseph Asemota; Oluwasegun Akinyemi; Mojisola O Araoye; Mohammed Saleh; Ahmed Ali; Ravi Sarma
Journal:  J Cancer Res Clin Oncol       Date:  2022-01-20       Impact factor: 4.553

10.  INCIDENCE AND TIME TREND OF HIP FRACTURES IN ROMANIA: A NATIONWIDE STUDY FROM 2008 TO 2018.

Authors:  D Grigorie; A Sucaliuc; M Ciutan; C Vladescu
Journal:  Acta Endocrinol (Buchar)       Date:  2019 Oct-Dec       Impact factor: 0.877

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.